Single-lesion Prostate-specific Membrane Antigen Protein Expression (PSMA) and Response to [(177)Lu]-PSMA-ligand Therapy in Patients with Castration-resistant Prostate Cancer

Initial reports of a clinical response in patients treated with the radioligand [(177)Lu]-PSMA-617 for castration-resistant prostate cancer (CRPC) are promising, despite known inter- and intrapatient heterogeneity. In metastatic CRPC, we examined the association of baseline immunohistochemical (IHC)...

Descripción completa

Detalles Bibliográficos
Autores principales: Stangl-Kremser, Judith, Rasul, Sazan, Tosoian, Jeffrey J., Salami, Simpa S., Zaslavsky, Alexander, Udager, Aaron, Mazal, Peter, Kain, Renate, Comperat, Eva, Hacker, Marcus, Haug, Alexander, Mitterhauser, Markus, Pozo-Salido, Carmen, Steinbach, Christina, Hassler, Melanie R., Kramer, Gero, Shariat, Shahrokh F., Palapattu, Ganesh S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Brief Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317820/
https://www.ncbi.nlm.nih.gov/pubmed/34337549
http://dx.doi.org/10.1016/j.euros.2021.06.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317820/
https://www.ncbi.nlm.nih.gov/pubmed/34337549
http://dx.doi.org/10.1016/j.euros.2021.06.007

Ejemplares similares